COLLEGIUM PHARMACEUTICAL INC

COLL

Latest QuantConomy context for COLL: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for COLL. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for COLL

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
earnings earnings release	neutral	40	Feb 26, 12:00 AM	COLL filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-26. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
corporate event other event	neutral	40	May 15, 08:20 PM	COLL filed 8-K: Shareholder Vote Results - [weak neutral signal]
corporate event acquisition disposition	bullish	95	May 12, 11:45 AM	COLL filed 8-K: Acquisition or Disposition, Director or Officer Changes, Regulation FD Disclosure - 3 material events - [very strong bullish signal]

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

Market	Exchange	Source	Asset record
COLL	NASDAQ	alpaca	Collegium Pharmaceutical, Inc. Common Stock
COLL	NASDAQ	alphavantage	Collegium Pharmaceutical Inc
COLL	NASDAQ	fmp	Collegium Pharmaceutical, Inc.

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
Jun 8, 2026	SANTINI GINO	Director	exercise	8,700	$16.49	$143,463	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.